Methods Compared Classifying Intensity of Soil-Transmitted Helminth Infections
|
By LabMedica International staff writers Posted on 23 Jul 2020 |

Image: The FECPAKG2 is an internet connected, image based diagnostic platform scientifically validated to conduct fecal egg count (FEC) tests (Photo courtesy of Techion).
Soil-transmitted helminths (Ascaris lumbricoides, Trichuris trichiura) and the hookworms, Necator americanus and Ancylostoma duodenale affect one quarter of the world population, and are responsible for the loss of more than three million disability-adjusted life years (DALYs).
There are a variety of novel microscopy and DNA-based methods to identify soil-transmitted helminths, but it remains unclear whether applying current World Health Organization (WHO) thresholds on to these methods allows for a reliable classification of moderate-to-heavy intensity (M&HI) infections.
An international team of scientists led by those at Ghent University (Merelbeke, Belgium) defined method-specific thresholds and verified whether they increased the correct classification of M&HI infections in a multi-countries study. They evaluated both WHO and method-specific thresholds for classifying the M&HI infections for novel microscopic methods: McMaster egg counting technique, FECPAKG2 (Techion, Aberystwyth, UK), and Mini-FLOTAC (Federico II University of Naples, Naples, Italy) and DNA-based (qPCR) diagnostic methods (Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands). The samples were also analyzed by Kato-Katz method as the reference method.
The team applied the WHO thresholds, the new microscopic methods mainly misclassified M&HI as low intensity, and to a lesser extent low intensity infection as M&HI. For FECPAKG2, applying the method-specific thresholds significantly improved the agreement for Ascaris (moderate → substantial), Trichuris and hookworms (fair → moderate). For Mini-FLOTAC, a significantly improved agreement was observed for hookworms only (fair → moderate). For the other STHs, the agreement was almost perfect and remained unchanged. For McMaster, the method-specific thresholds revealed a fair to a substantial agreement, but did not significantly improve the agreement. For qPCR, the method-specific thresholds based on genome equivalents per mL of DNA moderately agreed with the reference method for hookworms and Trichuris infections. For Ascaris, there was a substantial agreement.
The authors concluded that their results indicated that method-specific thresholds improved the classification of M&HI infections, but they stressed that validation studies are required before they can be recommended for general use in assessing M&HI infections in programmatic settings. The study also highlights the need (i) to agree on an absolute universal unit for qPCR, (ii) to align the evaluation of diagnostic methods with current STH program goals, and (iii) to define minimal and ideal (optimistic) criteria that diagnostic methods should meet in order to assess M&HI infections reliably. The study was published on July 2, 2020 in the journal PLOS Neglected Tropical Diseases.
Related Links:
Ghent University
Techion
Federico II University of Naples
Elisabeth-Tweesteden Hospital
There are a variety of novel microscopy and DNA-based methods to identify soil-transmitted helminths, but it remains unclear whether applying current World Health Organization (WHO) thresholds on to these methods allows for a reliable classification of moderate-to-heavy intensity (M&HI) infections.
An international team of scientists led by those at Ghent University (Merelbeke, Belgium) defined method-specific thresholds and verified whether they increased the correct classification of M&HI infections in a multi-countries study. They evaluated both WHO and method-specific thresholds for classifying the M&HI infections for novel microscopic methods: McMaster egg counting technique, FECPAKG2 (Techion, Aberystwyth, UK), and Mini-FLOTAC (Federico II University of Naples, Naples, Italy) and DNA-based (qPCR) diagnostic methods (Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands). The samples were also analyzed by Kato-Katz method as the reference method.
The team applied the WHO thresholds, the new microscopic methods mainly misclassified M&HI as low intensity, and to a lesser extent low intensity infection as M&HI. For FECPAKG2, applying the method-specific thresholds significantly improved the agreement for Ascaris (moderate → substantial), Trichuris and hookworms (fair → moderate). For Mini-FLOTAC, a significantly improved agreement was observed for hookworms only (fair → moderate). For the other STHs, the agreement was almost perfect and remained unchanged. For McMaster, the method-specific thresholds revealed a fair to a substantial agreement, but did not significantly improve the agreement. For qPCR, the method-specific thresholds based on genome equivalents per mL of DNA moderately agreed with the reference method for hookworms and Trichuris infections. For Ascaris, there was a substantial agreement.
The authors concluded that their results indicated that method-specific thresholds improved the classification of M&HI infections, but they stressed that validation studies are required before they can be recommended for general use in assessing M&HI infections in programmatic settings. The study also highlights the need (i) to agree on an absolute universal unit for qPCR, (ii) to align the evaluation of diagnostic methods with current STH program goals, and (iii) to define minimal and ideal (optimistic) criteria that diagnostic methods should meet in order to assess M&HI infections reliably. The study was published on July 2, 2020 in the journal PLOS Neglected Tropical Diseases.
Related Links:
Ghent University
Techion
Federico II University of Naples
Elisabeth-Tweesteden Hospital
Latest Technology News
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Channels
Clinical Chemistry
view channel
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read more
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read moreMolecular Diagnostics
view channel
Point-of-Care Molecular Technology Promises Transformative Shift in Oncology
Delays in obtaining molecular test results can hinder timely oncology decisions and widen disparities for patients far from centralized laboratories. Prolonged waits may also heighten anxiety and increase... Read more
New Test Delivers Four Prenatal Genetic Screens from One Blood Sample
Prenatal genetic screening often requires multiple tests, blood draws, and follow-up appointments, delaying access to clinically relevant information. Early, consolidated insights may help clinicians coordinate... Read more
Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
Vesicular and pustular skin lesions can stem from multiple viral pathogens, complicating timely diagnosis and management. Sequential single-pathogen testing can miss infections when the causative agent... Read more
Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
Radium-223 dichloride is a bone-targeted radiopharmaceutical therapy that improves overall survival and quality of life for many patients with metastatic castration-resistant prostate cancer (mCRPC), but... Read moreHematology
view channel
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read moreImmunology
view channel
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read morePathology
view channel
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
Tempus AI, Inc. (Chicago, IL, USA) has entered into a definitive agreement to acquire Personalis, Inc. (Fremont, CA, USA), expanding its capabilities in molecular residual disease (MRD) testing and cancer... Read more




 Assay.jpg)



